In Alzheimer’s disease, the neurons are dying leading to impaired memory and learning. AlzeCure Pharma has identified druglike compounds that stimulate neurotrophic signaling and the function of neurons resulting in improved memory.
NeuroRestore is a program containing symptomatic drug candidates for the treatment of diseases with a cognition dysfunction, such as Alzheimer’s disease. The three primary drug candidates are ACD855, ACD856 and ACD857.
We plan to initiate clinical studies with the first candidate drug in the NeuroRestore program in December 2018.
The video below briefly shows how a compound from the NeuroRestore program acts in the brain.